ClinicalTrials.gg
Active, not recruitingNCT05916092SPARTANUpdated Oct 27, 2026

Post-Market Clinical Study on a Modular SI Joint Fusion System

An observational study in Sacroiliitis and Sacroiliac Joint Dysfunction, sponsored by CornerLoc. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by CornerLoc · Observational

Updated Oct 27, 2026Now Active, not recruitingPrimary completion moved+1 moreGo to Updates ↓
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
240
Ages
18 Years to 85 Years
Sex
All
01

Study summary

A prospective study on the use of the TransLoc 3D SI Joint Fusion System for patients with sacroiliac joint disruptions or degenerative sacroiliitis.

Read the detailed description

Multicenter, prospective, post-market surveillance study on the TransLoc 3D Sacroiliac Joint Fusion System including two treatment arms: 1) Lateral-Oblique TransLoc 3D Screw(s), 2) Lateral Oblique TransLoc 3D Screw with Posterior Device (Hybrid). Data from this post-market study will be used to support knowledge of clinical efficacy and improvement with the use of TransLoc 3D Sacroiliac Joint Fusion System.

02

Conditions studied

  • Sacroiliitis
  • Sacroiliac Joint Dysfunction

Browse trials for

03

In context

Sacroiliitis

42 studies on the registry are indexed under Sacroiliitis; 11 are open to participants now.

This study's planned enrollment of 240 is above the median of 120 across 13 observational studies indexed under Sacroiliitis.

Browse Sacroiliitis studies →

Lead sponsor

CornerLoc is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Consecutive enrollment of all patients within inclusion criteria.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects meeting all of the following inclusion criteria by the end of the screening phase should be considered for admission to the study:

    • Age 18-85* (*Over 85 is allowed with H\&P assessment screening upon approval by Medical Monitor);
    • Absent condition of high-risk surgical candidate (see training manual for definition);
    • Patient has lower back pain with a confirmed diagnosis of sacroiliac joint disruption or degenerative sacroiliitis for a period of >6 months and who has not responded to optimal conservative care (PT or prescribed HEP, optimal medical management including NSAIDs);
    • Diagnosis of sacroiliac joint disruption or degenerative sacroiliitis based on ALL of the following: a. Patient has pain at or close to the posterior superior iliac spine (PSIS) with possible radiation into buttocks, posterior thigh or groin and can point with a single finger to the location of pain (Fortin Finger Test), and b. at least three positive findings with provocative maneuvers (FABER, Gaenslen, Thigh Thrust or Posterior Shear, SI Compression, SI Distraction, and Yeoman Test);
    • Patient has a diagnostic SIJ injection (SIJI) that provided a minimum of 75% relief of primary (index) pain with the diagnostic SIJI on two separate occasions;
    • Patient meets Medicare and payer requirements for medical necessity, see detailed requirements in training manual;
    • SI joint disruption: Asymmetric SI joint widening on X-ray or CT scan or degenerative sacroiliitis with radiographic evidence of SIJ degeneration as evidenced on CT or X-ray;
    • SI joint pain or instability with or without prior lumbar/lumbosacral surgery;
    • Baseline Oswestry Disability Index (ODI) score of at least 30%;
    • Baseline SI joint pain score of at least 60 on 0-100mm visual analog scale (or at least a 6 on NRS);
    • Patient has the necessary mental capacity to participate and is physically able to comply with study protocol requirements;
    • Failed SIJ fusion revisions can be included if all other inclusion criteria are met;
    • Patient must be able to communicate with study personnel via phone, text, or email;
    • PI must confirm women of childbearing years are not pregnant or plan to become pregnant prior to surgery;
    • Cardiac Clearance for patients with diagnosis of cardiac disease;
    • Patient has signed study-specific form.

Exclusion criteria

Exclusion Criteria:

  • Patient will not be entered into the study if they meet one of the following criteria:

    • Current severe back pain due to other causes, such as lumbar disc degeneration, lumbar disc herniation, lumbar spondylolisthesis, lumbar spinal stenosis, lumbar facet degeneration, lumbar radicular pain that extends beyond the mid-thigh, and lumbar vertebral body fracture;
    • SIJ pain secondary to inflammatory conditions or other known sacroiliac pathology such as: Sacral dysplasia, Inflammatory sacroiliitis (e.g., ankylosing spondylitis or other HLA-associated spondylo-arthropathy), Tumor or infection in the SI joint, Acute fracture or Crystal arthropathy;
    • History of recent (\<1 year) major trauma to pelvis (MVA or significant accident that results in acute injury to pelvis requiring hospitalization or surgery);
    • Previously diagnosed osteoporosis (defined as prior T-score \<-2.5 or history of osteoporotic fracture). If patient meets the osteoporosis screening criteria identified by the National Osteoporosis Foundation, they should be screened for osteoporosis with DEXA;
    • - patient who is currently not maintained on a medication regimen for treatment, and not stable (\<6 months without exacerbation);
    • Any condition or anatomy that makes treatment with the TransLoc 3D Sacroiliac Joint Fusion System infeasible;
    • Current local or systemic infection that raises the risk of surgery;
    • Patient currently receiving disability remuneration, and/or involved in injury litigation;
    • Patient is undergoing treatment under Workman's Compensation under a claim or injury greater than 1 year;
    • Patient is participating in an study or has been involved in an investigational study within 3 months prior to evaluation for participation;
    • Known to be pregnant, suspected pregnant, or planning to be pregnant prior to SIJ surgery;
    • Patient is a prisoner or a ward of the state;
    • Known or suspected drug or alcohol abuse;
    • Known allergy to titanium or titanium alloys;
    • Diagnosed psychiatric disease (e.g., schizophrenia, major depression, personality disorders) that is not well controlled for a minimum of two years and could interfere with study participation.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
240 participants (estimated)
Patient registry
No

Groups and cohorts

  • Lateral-Oblique TransLoc 3D Screw(s)

    Patients receiving the TransLoc 3D Screw(s) version will receive screw(s) placed lateral-obliquely into the intended SI joint.

    Device: TransLoc 3D

  • Lateral Oblique TransLoc 3D Screw with Posterior Device (Hybrid)

    Patients receiving the TransLoc 3D Hybrid construct will receive one 3D-printed titanium screw placed lateral-obliquely and one 3D-printed titanium posterior device across the same sacroiliac joint.

    Device: TransLoc 3D

Interventions

  • DeviceTransLoc 3D

    TransLoc 3D SI Joint Fusion System

06

What researchers measure

Primary outcomes

  1. Clinical improvement at 12 months defined by a composite score of functional status, pain, and safety events.

    Functional improvement and pain score have long been the standard for SI joint improvement measures. Multiple functional improvement scales will be assessed throughout the study.

    Time frame: 12 months

  2. Absence of Serious Adverse Events (SAEs)

    Demonstrate safety as defined by Serious Adverse Events (SAEs).

    Time frame: From the time informed consent is signed through 12 months.

Secondary outcomes

  1. Absence of study-related adverse events

    Evaluate any study-related adverse events for the duration of the study.

    Time frame: 6 months, 12 months

07

Study locations

1 site
  • NY Spine and Pain Specialists
    Port Jefferson Station, New York 11776, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Oct 2023 (actual). Primary completion is estimated for Aug 2027, 46 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: primary completion Dec 2025 → Aug 2027 and completion Jul 2026 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2023
First posted
Jun 23, 2023
StartActual
Oct 19, 2023
Primary completionEst.
Aug 2027was Dec 2025
CompletionEst.
Dec 2027was Jul 2026
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Enrolling by invitation→Active, not recruiting
changed Oct 27, 2026
Primary completion
Dec 2025→Aug 2027
Oct 27, 2026
Study completion
Jul 2026→Dec 2027
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Enrolling by invitation→Active, not recruiting
    Primary completion Dec 2025→Aug 2027
    Study completion Jul 2026→Dec 2027
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05916092
Lead sponsor
CornerLoc
Responsible party
Sponsor
First posted
Jun 23, 2023
Start date
Oct 19, 2023
Primary completion
Aug 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Oct 27, 2026

Study contacts

Samuel Brown, DO
principal investigator · NY Spine and Pain Specialists

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion